Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study

Abstract Background Concurrent chemo-radiotherapy remains the standard treatment in unresectable stage III non-small-cell lung cancer (NSCLC) patients. Several studies have shown a potential value of concurrent epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) with thoracic radio...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Lucheng ZHU, Changlin Zou, Zhanchun Zhang, Jianfang Wang, Li Yang, Chuangzhou Rao, Zhiping Yang, Jiafeng Liang, Bing Xia, M. A. Shenglin
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMC 2021-05-01
Ráidu:	BMC Cancer
Fáttát:	Almonertinib EGFR-TKI Radiotherapy Locally advanced NSCLC Radiation pneumonitis
Liŋkkat:	https://doi.org/10.1186/s12885-021-08266-w
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!